# CHISEL (NCT01014130)

> Hypofractionated Radiotherapy (Stereotactic) Versus Conventional Radiotherapy for Inoperable Early Stage I Non-small Cell Lung Cancer (NSCLC)

No report yet. It can be ordered.

- Drugs tested: none (the trial tests a strategy, not a drug)
- Indication: inoperable stage I non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01014130
- Phase: PHASE3
- Status: UNKNOWN
- Sponsor: Trans Tasman Radiation Oncology Group
- Conditions: Non Small Cell Lung Cancer
- Interventions: Hypofractionated radiotherapy (HypoRT); Conventionally Fractionated Radiotherapy (ConRT)
- Enrollment: 101
- Primary outcome: Time to Local Failure

## Indexed commentary on CHISEL so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 33 posts on X
- 1 YouTube video
- 1 podcast episode

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=chisel-nct01014130

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01014130", "email": "<work email>"}; the inbox owner confirms by the emailed link.